{"id":2064,"date":"2024-04-16T12:55:04","date_gmt":"2024-04-16T12:55:04","guid":{"rendered":"https:\/\/stoxpo.com\/?p=2064"},"modified":"2024-04-16T12:55:06","modified_gmt":"2024-04-16T12:55:06","slug":"palisade-bio-reports-promising-results-for-uc-treatment-pali-2108","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2024\/04\/16\/palisade-bio-reports-promising-results-for-uc-treatment-pali-2108\/","title":{"rendered":"Palisade Bio Reports Promising Results for UC Treatment PALI-2108"},"content":{"rendered":"\n

Successful Analysis Demonstrates Effective Bioactivation of Colon-Specific PDE4 Inhibitor Prodrug<\/h4>\n\n\n\n

Palisade Bio (PALI), a biopharmaceutical firm dedicated to advancing therapies for autoimmune, inflammatory, and fibrotic diseases, announces positive outcomes from its analysis of PALI-2108, an oral colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug for ulcerative colitis (UC) patients.<\/p>\n\n\n\n

The study, conducted in collaboration with Altasciences, confirms PALI-2108’s efficient conversion into its active form within stool samples from both healthy individuals and UC patients. LC-MS analysis revealed a mean conversion rate of 90.1% within a 24-hour timeframe, signaling the drug’s potential efficacy in managing UC.<\/p>\n\n\n\n

Dr. Mitch Jones, Palisade Bio’s CMO, expresses confidence in PALI-2108 as a targeted UC therapy, emphasizing its consistent and robust bioactivation profile. These findings underscore the drug’s promise as an innovative treatment option for moderate-to-severe UC, offering hope for patients seeking effective disease management strategies.<\/p>\n\n\n\n

Read original press release:here<\/mark><\/a><\/p>\n\n\n\n

You might like this article:Lockheed Martin Secures $17 Billion Contract for Next-Gen Interceptors<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Successful Analysis Demonstrates Effective Bioactivation of Colon-Specific PDE4 Inhibitor Prodrug Palisade Bio (PALI), a biopharmaceutical firm dedicated to advancing therapies for autoimmune, inflammatory, and fibrotic diseases, announces positive outcomes from its analysis of PALI-2108, an oral colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug for ulcerative colitis (UC) patients. The study, conducted in collaboration with Altasciences, confirms PALI-2108’s […]<\/p>\n","protected":false},"author":1,"featured_media":1422,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"1","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"1","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]}},"categories":[358,309],"tags":[],"coauthors":[453],"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2064"}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=2064"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2064\/revisions"}],"predecessor-version":[{"id":2065,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2064\/revisions\/2065"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1422"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=2064"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=2064"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=2064"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=2064"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}